• Takehiro Higashi, Junichi Tsukada, Chiaki Kato, Atsushi Iwashige, Takamitsu Mizobe, Shinichiro Machida, Hiroaki Morimoto, Ryosuke Ogawa, Yoko Toda, and Yoshiya Tanaka.
• First Department Internal Medicine, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan. jtsukada@med.uoeh-u.ac.jp
• Am. J. Hematol. 2004 Jul 1; 76 (3): 275-8.

AbstractAlthough imatinib mesylate has shown encouraging activity in chronic myelogenous leukemia (CML), disease progression during therapy has been observed, manifested by clonal expansion of imatinib mesylate-resistant leukemia cells. On the other hand, myelosuppression related to treatment of imatinib mesylate is often managed with temporary interruption of treatment or dose reduction. We here report two CML patients who had imatinib mesylate-sensitive blast crisis (BC) immediately after discontinuation of imatinib mesylate therapy. The patients discontinued therapy because of neutropenia. Although there was no evidence of blastic phase during therapy, BC occurred 2 weeks after the withdrawal of treatment in both cases. Interestingly, additional chromosomal abnormalities were detected following the withdrawal of imatinib mesylate and disappeared by re-introduction of this agent. The same doses of imatinib mesylate was still effective and remission was sustained with imatinib mesylate alone again. Our report suggests the possibility that withdrawal of imatinib mesylate may lead to proliferation of blast clones even in patients showing good responses to imatinib mesylate without signs of disease progression.Copyright 2004 Wiley-Liss, Inc.

35 keywords...

hide…